No cell therapy for tendon injury has FDA approval for commercial use. Investigational products have been used under emergency-access or clinical-trial exemptions in the United States, but the field remains pre-regulatory. European regulatory pathways are similarly undecided.
Tendons are specialised collagenous tissues that transmit muscle force to bone with minimal elasticity—a design that makes them prone to partial tears and degeneration when overstressed. Unlike muscle, tendons have poor intrinsic healing capacity due to limited blood supply and sparse resident cell populations. Recovery from tendon injury often stalls at a fibrotic scar that is weaker and less organised than native tissue. Cell therapy approaches employ placental MSCs, exosomes (acellular vesicles carrying molecular signals), and sometimes engineered chondrocytes to promote tissue remodelling and fibril alignment. The proposed mechanism involves delivering cells or their secreted factors directly to the injury site, where they are thought to reduce inflammation, promote angiogenesis (new blood vessel formation), and guide collagen deposition along physiologically correct orientations.
Am I a candidate? → · Tendon & Sports Injuries: full overview → · Tendon & Sports Injuries cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية